Media
Zhejiang Provincial Vice Governor Zhang Yanyun Visits Angel Pharmaceuticals for Inspection and Guidance
On the afternoon of May 5, Zhang Yanyun, Vice Governor of the People's Government of Zhejiang Province, visited Angel Pharmaceuticals for inspection and guidance. He was accompanied by relevant officials from the General Office of the Provincial Government, the Provincial Bureau of Financial Regulation, and the Hangzhou Central Sub-branch of the People's Bank of China, as well as Ni Huping, Deputy Mayor of Jiaxing City; Shao Panfeng, Secretary of the Nanhu District Committee; and Cao Jiandi, Member of the Standing Committee of the Nanhu District Committee and Deputy Secretary of the Party Working Committee of Nanhu High-tech Zone.
Vice Governor Zhang Yanyun and his delegation toured the Chemistry Innovation Drug Laboratory and the Biology Innovation Drug Laboratory at Angel Pharmaceuticals' Jiaxing R&D Headquarters. He learned about the company's development history from Dr. Wang Tiefei, Co-founder of Angel Pharmaceuticals, and received a detailed introduction from Dr. Li Kecheng, Vice President of the company, regarding the company's proprietary drug discovery platform being built on the basis of covalent chemistry for immune cell modulation.
Vice Governor Zhang Yanyun expressed appreciation for Angel Pharmaceuticals' mission of "benefiting Chinese patients by bringing globally top-tier innovative drugs for serious diseases such as cancer, autoimmune diseases, and infectious diseases to China." He affirmed the company's dual-driven model of "licensing-in plus independent R&D" and spoke highly of the company's development prospects. He also encouraged the company team to continue its efforts, with a focus on serving patients and society, to develop more "global first-in-class and best-in-class" innovative drugs and contribute to the advancement of public health.
About Angel Pharmaceuticals
Angel Pharmaceuticals is an innovative drug company dedicated to oncology and autoimmune diseases. With the mission of benefiting Chinese patients, Angel is committed to bringing globally top-tier innovative drugs for serious diseases such as cancer and autoimmune disorders to China. In October 2020, Angel Pharmaceuticals completed its Series A financing round, co-invested by Beta Fund, Hisun Pharmaceuticals, Tigermed, and Puhua Investment, and established a strategic partnership with Corvus Pharmaceuticals (CRVS) of the U.S. For more information, please visit www.angelpharma.com.
